Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2012

01.06.2012 | Original Article

Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans

verfasst von: Swen Hesse, Peter Brust, Peter Mäding, Georg-Alexander Becker, Marianne Patt, Anita Seese, Dietlind Sorger, Jörg Zessin, Philipp M. Meyer, Donald Lobsien, Sven Laudi, Bernd Habermann, Frank Füchtner, Julia Luthardt, Anke Bresch, Jörg Steinbach, Osama Sabri

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[11C]DASB is currently the most frequently used highly selective radiotracer for visualization and quantification of central SERT. Its use, however, is hampered by the short half-life of 11C, the moderate cortical test–retest reliability, and the lack of quantifying endogenous serotonin. Labelling with 18F allows in principle longer acquisition times for kinetic analysis in brain tissue and may provide higher sensitivity. The aim of our study was to firstly use the new highly SERT-selective 18F-labelled fluoromethyl analogue of (+)-McN5652 ((+)-[18F]FMe-McN5652) in humans and to evaluate its potential for SERT quantification.

Methods

The PET data from five healthy volunteers (three men, two women, age 39 ± 10 years) coregistered with individual MRI scans were semiquantitatively assessed by volume-of-interest analysis using the software package PMOD. Rate constants and total distribution volumes (V T) were calculated using a two-tissue compartment model and arterial input function measurements were corrected for metabolite/plasma data. Standardized uptake region-to-cerebellum ratios as a measure of specific radiotracer accumulation were compared with those of a [11C]DASB PET dataset from 21 healthy subjects (10 men, 11 women, age 38 ± 8 years).

Results

The two-tissue compartment model provided adequate fits to the data. Estimates of total distribution volume (V T) demonstrated good identifiability based on the coefficients of variation (COV) for the volumes of interest in SERT-rich and cortical areas (COV V T <10%). Compared with [11C]DASB PET, there was a tendency to lower mean uptake values in (+)-[18F]FMe-McN5652 PET; however, the standard deviation was also somewhat lower. Altogether, cerebral (+)-[18F]FMe-McN5652 uptake corresponded well with the known SERT distribution in humans.

Conclusion

The results showed that (+)-[18F]FMe-McN5652 is also suitable for in vivo quantification of SERT with PET. Because of the long half-life of 18F, the widespread use within a satellite concept seems feasible.
Literatur
1.
Zurück zum Zitat D'Amato RJ, Largent BL, Snowman AM, Snyder SH. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther. 1987;242:364–71.PubMed D'Amato RJ, Largent BL, Snowman AM, Snyder SH. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther. 1987;242:364–71.PubMed
2.
Zurück zum Zitat Hesse S, Barthel H, Schwarz J, Sabri O, Müller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev. 2004;28:547–63.PubMedCrossRef Hesse S, Barthel H, Schwarz J, Sabri O, Müller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev. 2004;28:547–63.PubMedCrossRef
3.
Zurück zum Zitat Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32:86–102.PubMed Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32:86–102.PubMed
4.
Zurück zum Zitat Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 2005;140:63–72.PubMedCrossRef Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 2005;140:63–72.PubMedCrossRef
5.
Zurück zum Zitat Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacol (Berl). 2007;195:315–24.CrossRef Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacol (Berl). 2007;195:315–24.CrossRef
6.
Zurück zum Zitat Szabo Z, Owonikoko T, Peyrot M, Varga J, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry. 2004;55:766–71.PubMedCrossRef Szabo Z, Owonikoko T, Peyrot M, Varga J, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry. 2004;55:766–71.PubMedCrossRef
7.
Zurück zum Zitat McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl). 2008;200:439–50.CrossRef McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl). 2008;200:439–50.CrossRef
8.
Zurück zum Zitat Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner Jr HN. [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci. 1993;53:883–92.PubMedCrossRef Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner Jr HN. [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci. 1993;53:883–92.PubMedCrossRef
9.
Zurück zum Zitat Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103–10.PubMedCrossRef Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103–10.PubMedCrossRef
10.
Zurück zum Zitat Ogden RT, Ojha A, Erlandsson K, Oquendo MA, Mann JJ, Parsey RV. In vivo quantification of serotonin transporters using [11C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab. 2007;27:205–17.PubMedCrossRef Ogden RT, Ojha A, Erlandsson K, Oquendo MA, Mann JJ, Parsey RV. In vivo quantification of serotonin transporters using [11C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab. 2007;27:205–17.PubMedCrossRef
11.
Zurück zum Zitat Talbot PS, Frankle WG, Hwang DR, Huang Y, Suckow RF, Slifstein M, et al. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse. 2005;55:164–75.PubMedCrossRef Talbot PS, Frankle WG, Hwang DR, Huang Y, Suckow RF, Slifstein M, et al. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse. 2005;55:164–75.PubMedCrossRef
12.
Zurück zum Zitat Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, et al. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging. 2010;37:545–55.PubMedCrossRef Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, et al. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging. 2010;37:545–55.PubMedCrossRef
13.
Zurück zum Zitat Stehouwer JS, Goodman MM. Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: dopamine, serotonin, and norepinephrine. PET Clin 2009;4:101–28.PubMedCrossRef Stehouwer JS, Goodman MM. Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: dopamine, serotonin, and norepinephrine. PET Clin 2009;4:101–28.PubMedCrossRef
14.
Zurück zum Zitat Huang Y, Zheng MQ, Gerdes JM. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem. 2010;10:1499–526.PubMed Huang Y, Zheng MQ, Gerdes JM. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem. 2010;10:1499–526.PubMed
15.
Zurück zum Zitat Zessin J, Eskola O, Brust P, Bergman J, Steinbach J, Lehikoinen P, et al. Synthesis of S-([18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. Nucl Med Biol. 2001;28:857–63.PubMedCrossRef Zessin J, Eskola O, Brust P, Bergman J, Steinbach J, Lehikoinen P, et al. Synthesis of S-([18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. Nucl Med Biol. 2001;28:857–63.PubMedCrossRef
16.
Zurück zum Zitat Kretzschmar M, Brust P, Zessin J, Cumming P, Bergmann R, Johannsen B. Autoradiographic imaging of the serotonin transporter in the brain of rats and pigs using S-([18F]fluoromethyl)-(+)-McN5652. Eur Neuropsychopharmacol. 2003;13:387–97.PubMedCrossRef Kretzschmar M, Brust P, Zessin J, Cumming P, Bergmann R, Johannsen B. Autoradiographic imaging of the serotonin transporter in the brain of rats and pigs using S-([18F]fluoromethyl)-(+)-McN5652. Eur Neuropsychopharmacol. 2003;13:387–97.PubMedCrossRef
17.
Zurück zum Zitat Marjamäki P, Zessin J, Eskola O, Grönroos T, Haaparanta M, Bergman J, et al. S-[18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse. 2003;47:45–53.PubMedCrossRef Marjamäki P, Zessin J, Eskola O, Grönroos T, Haaparanta M, Bergman J, et al. S-[18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse. 2003;47:45–53.PubMedCrossRef
18.
Zurück zum Zitat Brust P, Zessin J, Kuwabara H, Pawelke B, Kretzschmar M, Hinz R, et al. Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse. 2003;47:143–51.PubMedCrossRef Brust P, Zessin J, Kuwabara H, Pawelke B, Kretzschmar M, Hinz R, et al. Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse. 2003;47:143–51.PubMedCrossRef
19.
Zurück zum Zitat Brust P, Hinz R, Kuwabara H, Hesse S, Zessin J, Pawelke B, et al. In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology. 2003;28:2010–9.PubMedCrossRef Brust P, Hinz R, Kuwabara H, Hesse S, Zessin J, Pawelke B, et al. In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology. 2003;28:2010–9.PubMedCrossRef
20.
Zurück zum Zitat Hesse S, Stengler K, Regenthal R, Patt M, Becker GA, Franke A, et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011;14:606–17.PubMedCrossRef Hesse S, Stengler K, Regenthal R, Patt M, Becker GA, Franke A, et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011;14:606–17.PubMedCrossRef
21.
Zurück zum Zitat Bertoldo A, Cobelli C. Physiological modelling of positron emission tomography images. In: Carson E, Cobelli C, editors. Modelling methodology for physiology and medicine. San Diego: Academic Press; 2001. p. 179–211.CrossRef Bertoldo A, Cobelli C. Physiological modelling of positron emission tomography images. In: Carson E, Cobelli C, editors. Modelling methodology for physiology and medicine. San Diego: Academic Press; 2001. p. 179–211.CrossRef
22.
Zurück zum Zitat Carson RE. Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert HR, editors. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press; 1986. p. 347–90. Carson RE. Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert HR, editors. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press; 1986. p. 347–90.
23.
Zurück zum Zitat Buck A, Gucker PM, Schönbächler RD, Arigoni M, Kneifel S, Vollenweider FX, et al. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab. 2000;20:253–62.PubMedCrossRef Buck A, Gucker PM, Schönbächler RD, Arigoni M, Kneifel S, Vollenweider FX, et al. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab. 2000;20:253–62.PubMedCrossRef
24.
Zurück zum Zitat Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med. 2000;41:1465–77.PubMed Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med. 2000;41:1465–77.PubMed
25.
Zurück zum Zitat Ibaraki M, Miura S, Shimosegawa E, Sugawara S, Mizuta T, Ishikawa A, et al. Quantification of cerebral blood flow and oxygen metabolism with 3-dimensional PET and 15O: validation by comparison with 2-dimensional PET. J Nucl Med. 2008;49:50–9.PubMedCrossRef Ibaraki M, Miura S, Shimosegawa E, Sugawara S, Mizuta T, Ishikawa A, et al. Quantification of cerebral blood flow and oxygen metabolism with 3-dimensional PET and 15O: validation by comparison with 2-dimensional PET. J Nucl Med. 2008;49:50–9.PubMedCrossRef
Metadaten
Titel
Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans
verfasst von
Swen Hesse
Peter Brust
Peter Mäding
Georg-Alexander Becker
Marianne Patt
Anita Seese
Dietlind Sorger
Jörg Zessin
Philipp M. Meyer
Donald Lobsien
Sven Laudi
Bernd Habermann
Frank Füchtner
Julia Luthardt
Anke Bresch
Jörg Steinbach
Osama Sabri
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2078-z

Weitere Artikel der Ausgabe 6/2012

European Journal of Nuclear Medicine and Molecular Imaging 6/2012 Zur Ausgabe